Get the Stockscreener App
10.27
1.78%
0.18
After Hours:
10.27
Neogenomics Inc stock is traded at $10.27, with a volume of 1.43M.
It is up +1.78% in the last 24 hours and up +3.11% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$10.09
Open:
$10.01
24h Volume:
1.43M
Relative Volume:
1.05
Market Cap:
$1.23B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-16.56
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
+7.54%
1M Performance:
+3.11%
6M Performance:
-21.42%
1Y Performance:
-25.85%
1-Day Range:
$9.8686
$10.29
1-Week Range:
$9.305
$10.44
52-Week Range:
$8.05
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
10.27 | 1.23B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
424.24 | 159.25B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.14 | 132.37B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
437.44 | 32.95B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
106.28 | 28.58B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
150.28 | 24.90B | 15.41B | 1.37B | 2.11B | 7.50 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Bank of Montreal Can - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting - Business Wire
Learn to Evaluate (NEO) using the Charts - news.stocktradersdaily.com
Deep Dive Into NeoGenomics Stock: Analyst Perspectives (5 Ratings) - Benzinga
BofA Securities Adjusts Price Target on NeoGenomics to $12 From $16, Maintains Neutral Rating - marketscreener.com
Former AstraZeneca exec takes over as CEO of $660M Fort Myers lab firm - Business Observer
Form DEF 14A NEOGENOMICS INC For: Dec 31 - StreetInsider
SEC Form DEF 14A filed by NeoGenomics Inc. - Quantisnow
NeoGenomics (NASDAQ:NEO investor five-year losses grow to 68% as the stock sheds US$85m this past week - simplywall.st
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025 - BioSpace
NeoGenomics acquires Pathline - Medical Buyer
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
NeoGenomics expands with Pathline acquisition in Northeast US - Investing.com Australia
NeoGenomics expands with Pathline acquisition in Northeast US By Investing.com - Investing.com South Africa
NeoGenomics completes acquisition of Pathline - Gulfshore Business
NeoGenomics Completes Acquisition of Pathline - BioSpace
NeoGenomics Closes Pathline Acquisition - MarketScreener
NeoGenomics (NEO) Completes Acquisition of Pathline - StreetInsider
NeoGenomics Schedules its Second Quarter Earnings Release for July 30, 2019 - ACCESS Newswire
NeoGenomics Announces Grand Opening of New Pharma Services Laboratory in Singapore - ACCESS Newswire
NeoGenomics stock hits 52-week low at $8.9 amid challenges By Investing.com - Investing.com South Africa
NeoGenomics stock hits 52-week low at $8.9 amid challenges - Investing.com
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO) - Yahoo Finance
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes - ACCESS Newswire
NeoGenomics Schedules its First Quarter Earnings Release for April 30, 2019 - ACCESS Newswire
NeoGenomics announces CEO transition - MSN
New CEO assumes role at NeoGenomics - Gulfshore Business
(NEO) Trading Report - news.stocktradersdaily.com
NeoGenomics appoints Tony Zook as CEO - Investing.com
NeoGenomics, Inc. Announces CEO Changes - MarketScreener
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics - BioSpace
NeoGenomics appoints Tony Zook as CEO By Investing.com - Investing.com Australia
NeoGenomics Appoints Tony Zook Chief Executive - MarketScreener
NeoGenomics' New CEO Zook Takes Over as Smith Retires - MarketWatch
Tony Zook Assumes Role As Chief Executive Officer Of Neogenomics - MarketScreener
Benchmark maintains Hold on Neogenomics stock, reiterates price target By Investing.com - Investing.com Canada
Where are the Opportunities in (NEO) - news.stocktradersdaily.com
3 Reasons to Sell NEO and 1 Stock to Buy Instead - Yahoo Finance
Piper Sandler maintains Neogenomics stock with $18 target - Investing.com
Piper Sandler maintains Neogenomics stock with $18 target By Investing.com - Investing.com UK
NeoGenomics elevates Warren Stone to President and COO By Investing.com - Investing.com Australia
NeoGenomics Promotes Warren Stone to President & COO - TipRanks
Fort Myers-based NeoGenomics names new COO - Gulfshore Business
Earnings call transcript: NeoGenomics Q4 2024 results disappoint despite EPS beat - Investing.com
NeoGenomics elevates Warren Stone to President and COO - Investing.com
NeoGenomics Names Warren Stone President, COO -March 18, 2025 at 08:09 am EDT - Marketscreener.com
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer - Lelezard
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):